New drug HRS-9813 aims to slow lung scarring in fibrosis patients
NCT ID NCT07192939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HRS-9813 in 270 adults with pulmonary fibrosis (IPF or PPF), a condition where lung tissue becomes scarred and breathing gets harder. The trial compares the drug to a placebo to see if it improves lung function and is safe. Participants take the drug or placebo for a period, and doctors measure breathing tests and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact